Category

North America Anti-Rheumatic Drug Market Size, Share, Opportunities And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Type Of Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, Over-the-counter (OTC)) And By Country - Forecasts From 2020 To 2025.

Published: Jun 2020 | Report Code:  KSI061613648 | Pages:  90

North America Antirheumatic Drugs market was valued at US$8,988.317 million in 2019. The booming aging population in countries like the United States and Canada is the major driver of the antirheumatic drugs market in this region. According to the United States Census Bureau, all baby boomers will be older than age 65 by 2030, expanding the size of the older population such that 1 in every 5 residents will be at retirement age. According to the data provided by the Government of Canada, almost one in seven Canadians was above 65 in 2012 which is projected to rise to nearly one in four by 2030. Since arthritis problems are more common in this age group, this projection of the geriatric population will continue to drive the antirheumatic drugs market in North America throughout the forecast period.

The presence of major market players in the country also contributes to the market growth of antirheumatic drugs in the U.S. FDA (Food and Drug Administration) has approved many antirheumatic drugs in the recent past years, particularly in 2017, which is also boosting the country’s market growth. For example, abaloparatide was approved in April 2017 for post-menopausal women with osteoporosis and a high risk of fracture. In August 2019, FDA approved AbbVie’s RINVOQ®, 15 mg, once-daily oral JAK (Janus Kinase) inhibitor for the treatment of moderate to severe rheumatoid arthritis in adults with zero tolerance or inadequate response to methotrexate (MTX-IR).In Canada as well, AbbVie has got approval for its RINVOQ® from Health North America. As such, the market for anti-rheumatic drugs in North America will continue to grow at a substantial rate during the forecast period. The availability of over-the-counter (OTC) drugs to treat rheumatic diseases is further boosting the market growth of the antirheumatic drugs market in North America.

The North American Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, North America Anti-rheumatic Drug market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC). By country, the North American antirheumatic drugs market is segmented as the United States, Canada, and Mexico.  

Segmentation

  • By Type of Disease
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Gout
    • Lupus
    • Others
  • By Type of Molecule
    • Pharmaceuticals
    • Biopharmaceuticals
  • By Sales Channel
    • Prescription
    • Over-The-Counter (OTC)
  • By Country
    • Unites States
    • Canada
    • Mexico

OUR CLIENTS